EB病毒Rta蛋白抗体IgG在鼻咽癌诊断中的应用

Applying EBV Rta-IgG in diagnosis of nasopharyngeal carcinoma

目的检测EB病毒Rta蛋白抗体IgG在鼻咽癌初治患者血清中的表达水平,并探讨其与鼻咽癌临床分期的关系。方法采用酶联免疫吸附试验检测274例鼻咽癌未治疗患者及353例健康体检者血清中Rta-IgG水平,比较鼻咽癌患者和健康体检者Rta-IgG的表达水平及与临床分期的关系。结果鼻咽癌组与对照组比较,Rta-IgG表达水平的差异有统计学意义(P<0.01)。Rta-IgG表达水平与鼻咽癌临床分期无统计学意义(P>0.05)。结论应用ELISA法检测Rta-IgG的表达可以应用于鼻咽癌的诊断和鉴别诊断,但与鼻咽癌临床分期无关。

Objective To detect the expression level of Rta-IgG in the untreated patients with nasopharyngeal carcinoma （NPC）. Methods The diagnostic kit for IgG antibody to EBV Rta （ELISA） was used to test serum samples derived from 274 patients that were within different clinical stages confirmed by pathology examination, and 353 healthy controls. Results Significant difference of Rta-IgG positive rate between NPC group and healthy control group was revealed （P 〈 0.01 ）. However, the expression levels of Rta-IgG in NPC patients＇serum were irrelative with the clinical stage of the tumor. The A value was significantly higher in NPC group than that in healthy control group （P 〈 0.01 ）. Conclusion Rta-IgG is a sensitive and specific serologic parameter for NPC diagnosis, but it is not a proper marker for evaluating the clinical stage of NPC.